Search results for "Highlights"
Spotlight on diabetes drug class comparisons
A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
https://diabetes.acponline.org/archives/2022/10/14/5.htm
14 Oct 2022
Vitamin D may reduce risk of progression to diabetes from prediabetes
In adults with prediabetes, high-dose vitamin D was associated with a 12% to 15% reduced risk for diabetes compared with placebo, a systematic review and meta-analysis found, but an editorial cautioned about the uncertain risk of adverse effects.
https://diabetes.acponline.org/archives/2023/02/10/3.htm
10 Feb 2023
GLP-1 receptor agonists associated with better primary CV prevention vs. DPP-4 inhibitors
A retrospective study compared cardiovascular (CV) outcomes among patients adding glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin, sulfonylurea, or insulin treatment alone or in combination.
https://diabetes.acponline.org/archives/2023/05/12/3.htm
12 May 2023
No differences found in effects of secondary diabetes drugs on kidney outcomes
A trial found similar rates of progression to kidney disease among patients with type 2 diabetes who were randomized to add a sulfonylurea, a dipeptidyl peptidase-4 inhibitor, a glucagon-like peptide-1 receptor agonist, or basal insulin to metformin treatment.
https://diabetes.acponline.org/archives/2023/06/09/1.htm
9 Jun 2023
Overnight glucose associated with next-day functioning in adults with type 1 diabetes
More variation in overnight glucose levels and time spent above and below glucose targets were associated with adverse changes in measures of next-day function, including attention, sedentary time, and engagement in demanding activities, a study found.
https://diabetes.acponline.org/archives/2023/03/10/2.htm
10 Mar 2023
Social, medical intervention improved glycemic control in rural patients with diabetes
A population health team assessed patients' medical, behavioral, and social needs with annual health risk assessments and partnered with community organizations to improve their access to food, transportation, and medicine.
https://diabetes.acponline.org/archives/2023/03/10/3.htm
10 Mar 2023
ACP Journal Club: SGLT-2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
The results of this meta-analysis of sodium-glucose cotransporter-2 (SGLT-2) inhibitors highlight the opportunity for internists, nephrologists, endocrinologists, and cardiologists to collaborate to expand use of the drug class, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/03/10/7.htm
10 Mar 2023
Younger patients often ration insulin due to cost, study finds
Data from the 2021 National Health Interview Survey indicate that one in five patients younger than age 65 years, who would not be eligible for the $35 monthly Medicare price cap, have skipped or reduced insulin doses or put off buying the drug to save money.
https://diabetes.acponline.org/archives/2023/04/14/3.htm
14 Apr 2023
HbA1c at diagnosis may predict metformin failure, study finds
A model that included baseline HbA1c level, age, sex, and race/ethnicity had high discrimination for predicting failure risk, with the strongest association seen for HbA1c.
https://diabetes.acponline.org/archives/2023/01/13/2.htm
13 Jan 2023
NSAID use linked to risk of heart failure hospitalization in type 2 diabetes
Danish patients with type 2 diabetes who took prescription NSAIDs had increased risk of first-time heart failure hospitalization, particularly if they were new users of the drugs or age 65 years or older, a recent study found.
https://diabetes.acponline.org/archives/2023/04/14/2.htm
14 Apr 2023